NeoImmuneTech, Inc. is a clinical-stage biopharmaceutical company. which engages in the development of T cell-centered novel immunotherapeutics. The firm develops its product NT-I7 for the treatment of lymphopenia. The company was founded by Se Hwan Yang in January 2014 and is headquartered in Rockville, MD.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company